CPI leads UK biomanufacturing and pharma SME delegation on strategic visit to India

Funded by the UK Government and delivered as part of the Technology Security Initiative and the UK – India Net Zero Innovation Partnership, the visit represents a key contribution to the d UK – India Vision 2035 roadmap. It rerces the growing strategic ties between the two nations in biomanufacturing, pharmaceutical innovation and sustainable manufacturing, while also supporting UK innovators to access global markets and partnerships.

Mumbai: Market insight and industry engagement

The delegation’s visit began in Mumbai with engagement at CHEMTECH World Expo 2026, one of India’s flagship events for the chemical, pharmaceutical and advanced manufacturing sectors. During the first leg of the programme, delegates met with government officials, industry leaders, investors and prospective collaborators to gain insight into India’s rapidly evolving life sciences landscape and market opportunities. 

The delegation was welcomed on the first day in Mumbai by Jamie Scattergood, Deputy Head of Mission, and Mark Birrell, Trade Counsellor for Business and Trade, at the British Deputy High Commission Mumbai, with support from the British High Commission in India. 

Gareth Wynn Owen, British Deputy High Commissioner, Hyderabad British High Commission in India, said: ​“The UK – India partnership in life sciences and biomanufacturing continues to go from strength to strength. Delegations such as this play a vital role in connecting innovative UK SMEs with India’s dynamic ecosystem, supporting collaboration, trade and investment. We are pleased to support CPI and the delegation as they build relationships that contribute to d growth and the ambitions set out in the UK – India Vision 2035.”

Hyderabad: Deepening collaboration and R&D exchange

Following the Mumbai programme, the delegation travelled to Hyderabad for a series of site visits and strategic discussions with leading innovation partners. Highlights included visits to IKP Knowledge Park and the Centre for DNA Fingerprinting and Diagnostics (CDFD), enabling deeper scientific dialogue and R&D exchange. 

The delegation was joined in Hyderabad by Gareth Wynn Owen, who engaged directly with SMEs throughout the visit. 

In Hyderabad, delegates were welcomed by senior industry leaders, including Dr Satya Prakash Dash, CEO of IKP Knowledge Park, who d insights on the global biomanufacturing landscape and opportunities for UK – India collaboration. 

Dr Satya Prakash Dash, CEO, IKP Knowledge Park, said: ​“It was a pleasure to welcome CPI and the UK SME delegation to IKP Knowledge Park. The visit highlighted the strong alignment between the UK and India in advancing biomanufacturing, life sciences and sustainable innovation. We see significant opportunity for collaboration across R&D, scale-up and commercialisation, and this engagement marks an important step towards building long-term partnerships that can deliver global impact.” 

Looking ahead

The delegation marks an important milestone in CPI’s ongoing mission to support UK SMEs in scaling internationally, securing investment and building trusted global partnerships. As India’s life sciences and pharmaceutical sectors continue to grow, this visit has laid strong foundations for future collaboration that will drive innovation, economic growth and d global impact.

Showcasing UK SME innovation

CPI is proud to support the following UK SMEs on this delegation, each representing cutting-edge innovation across biopharma, biotech and pharmaceutical manufacturing: 

• MESOX

• PolyModels Hub

• Leucid Bio

• University of York

• ID Health Limited

• UCL

• Multus

• Biofuel Evolution

• Neobe Therapeutics

• Cotton Mouton Diagnostics Limited

• GutSee Health

• Sainc Biotech

• Antimicrobial Materials, Inc.

• Magellan Life Sciences Limited

• Mercel Ltd

• Frontier Space

• BioOrbit

• Atelerix Ltd.

• X‑Genix

• London Bioprocess

• Mass Balance

• Pathfinder Bio

These SMEs span a diverse range of technologies, from diagnostics and bioanalytics to advanced manufacturing platforms, and are uniquely positioned to capitalise on opportunities for R&D partnerships, market entry and scale-up within India’s life sciences sector.